J Korean Neurosurg Soc.  2022 Jul;65(4):499-506. 10.3340/jkns.2021.0197.

Evaluation of P57, P53 and Ki67 Expression in Meningiomas

• Küçükosmanoğlu İ
• Karanis MİE
• Ünlü Y
• Çöven İ

• KMID: 2531618
• DOI: http://doi.org/10.3340/jkns.2021.0197

Abstract

Objective
: We conducted this study with the aim of predicting the biological behavior of meningiomas, and determining the benefits of associating histological subtype and grade with the expression of proliferative markers and tumor suppressor proteins.
Methods
: The study included 29 patients with primary intracranial and intraspinal meningioma diagnosed in the pathology laboratory of Konya City Hospital between January 2014 and December 2020. Clinicopathological characteristics of the patients including parameters such as age and gender were obtained from the hospital records. Histopathological findings were obtained by re-evaluating the preparations stained with Hematoxylin-Eosin, which were extracted from the archive, and by evaluating new sections obtained from paraffin blocks of patients stained with Ki67, p53, and p57 immunohistochemical stains.
Results
: A moderate correlation was found between tumor size and Ki67 proliferation index (PI) (p=0.003, r=0.530). There was no significant difference between grade I and grade II tumors in terms of p53 (p=0.184) and p57 (p=0.487) expressions. There were higher levels of Ki67 PI in grade II tumors. The histological subtypes of the tumor had no significant difference with Ki67 PI (p=0.018), p53 (p=0.662), and p57 (p=0.368) expressions.
Conclusion
: In order to obtain more definitive results, there is a need for studies, which are conducted with a greater number of patients and in multiple centers, and in which a long prospective follow-up is planned. The combination of histological, surgical, and imaging markers could make a more sensitive tool for predicting recurrence, and this could also be tested in future studies.

Keyword

Pathology; Meningioma; Tumor biomarkers

Figure

• 

  Fig. 1. Histopathological subtypes of meningioma, staining with Hematoxylin-Eosin. A : Meningothelial type (×100). B : Transitional type (×100). C : Psammomatous type (×200). D : Atypical type (×400).

• 

  Fig. 2. High expression of p57 (×200 magnification).

• 

  Fig. 3. High Ki67 proliferation index (×100 magnification).

• 

  Fig. 4. Score 3 staining pattern for p53 (×200 magnification).

Reference

References

1. Abry E, Thomassen IØ, Salvesen ØO, Torp SH. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study. Pathol Res Pract. 206:810–815. 2010.

2. Cho H, Ha SY, Park SH, Park K, Chae YS. Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas. J Korean Med Sci. 14:199–205. 1999.

3. Csonka T, Murnyák B, Szepesi R, Bencze J, Bognár L, Klekner A, et al. Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence. Folia Neuropathol. 54:114–126. 2016.

4. De Carvalho GTC, Da Silva-Martins WC, De Magalhães KCSF, Nunes CB, Soares AN, Tafuri LSA, et al. Recurrence/regrowth in grade I meningioma: how to predict? Front Oncol. 10:1144. 2020.

5. Kumar S, Kakkar A, Suri V, Kumar A, Bhagat U, Sharma MC, et al. Evaluation of 1p and 14q status, MIB-1 labeling index and progesterone receptor immunoexpression in meningiomas: adjuncts to histopathological grading and predictors of aggressive behavior. Neurol India. 62:376–382. 2014.

6. Lam WW, Hatada I, Ohishi S, Mukai T, Joyce JA, Cole TR, et al. Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic beckwith-wiedemann syndrome (BWS) provides a novel genotypephenotype correlation. J Med Genet. 36:518–523. 1999.

7. Latic D, Pejic S, Savic S, Loncar Z, M Nikolic I, Nikolic G, et al. Cyclin D1 and p57 expression in relation to clinicopathological characteristics and overall survival in patients with renal cell carcinoma. J BUON. 24:301–309. 2019.

8. Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131:803–820. 2016.

9. Madhuri TK, Tailor A, Haagsma B, Coley H, Butler-Manuel S. Relevance of immunohistochemical expression of p57kip2 in epithelial ovarian carcinoma- a systematic literature review. J Ovarian Res. 5:46. 2012.

10. Mehidine H, Refregiers M, Jamme F, Varlet P, Juchaux M, Devaux B, et al. Molecular changes tracking through multiscale fluorescence microscopy differentiate meningioma grades and non-tumoral brain tissues. Sci Rep. 11:3816. 2021.

11. Pavelin S, Becic K, Forempoher G, Mrklic I, Pogorelic Z, Titlic M, et al. Expression of Ki-67 and p53 in meningiomas. Neoplasma. 60:480–485. 2013.

12. Pećina-Šlaus N, Kafka A, Vladušić T, Tomas D, Logara M, Skoko J, et al. Loss of p53 expression is accompanied by upregulation of beta-catenin in meningiomas: a concomitant reciprocal expression. Int J Exp Pathol. 97:159–169. 2016.

13. Rossi MN, Antonangeli F. Cellular response upon stress: p57 contribution to the final outcome. Mediators Inflamm. 2015:259325. 2015.

14. Telugu RB, Chowhan AK, Rukmangadha N, Patnayak R, Phaneendra BV, Prasad BC, et al. Histopathological and immunohistochemical evaluation of meningiomas with reference to proliferative markers p53 and Ki-67. J Clin Diagn Res. 10:EC15–EC19. 2016.

15. Tesio M, Trumpp A. Breaking the cell cycle of HSCs by p57 and friends. Cell Stem Cell. 9:187–192. 2011.

16. Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry. 79:574–580. 2008.

17. Zhang X. Expression, correlation and prognostic significance of CD133, P57 and HSF1 in meningioma. Eur Rev Med Pharmacol Sci. 21:4600–4605. 2017.